Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab in NY-ESO-1 positive advanced melanoma
NCT01216696Phase 2Completed
- Sponsor
- National Center for Tumor Diseases
- Start
- Nov 2010
- Primary completion
- Aug 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in melanoma, sponsored by National Center for Tumor Diseases. Primary endpoint: Disease Control Rate at 1 year. Started Nov 2010; status: completed.
02
Drugs
ipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01216696.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01216696.